<DOC>
	<DOCNO>NCT00513851</DOCNO>
	<brief_summary>Open label , phase 1 , dose escalation</brief_summary>
	<brief_title>Phase 1 Study OSI-930 Cancer Patients</brief_title>
	<detailed_description>Multicenter , open-label , phase 1 , dose escalation study determine maximum tolerate dose daily ( QD ) twice daily ( BID ) schedule . Patients may continue receive OSI-930 one follow occurs : disease progression , adverse event require withdrawal , failure recover toxicity despite 14-day dosing interruption , medical ethical reason , patient request , patient death .</detailed_description>
	<criteria>Histologically cytologically document malignancy advance and/or metastatic refractory establish form therapy effective therapy exists . Age &gt; /= 18 year , ECOG PS 02 , life expectancy &gt; /= 12 week Prior chemotherapy permit provide minimum 3 week elapse . Prior tyrosine kinase inhibitor therapy permit . Patients must recover treatmentrelated toxicity ( exception ) prior registration . Prior hormonal therapy permit provided discontinue prior registration ( exception prostate cancer patient hormone therapy least 3 month ) . Prior radiation therapy permit provide exceed 25 % bone marrow reserve patient recover toxic effect . A minimum 21 day must elapse unless radiotherapy palliative nonmyelosuppressive . ANC &gt; /= 1.5 x 10^9/L , PLT &gt; /= 100 x 10^9/L ; bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) , AST ALT &lt; /= 2.5 x ULN ; creatinine &lt; /= 1.5 ULN Accessible repeat dose followup . Patients must practice effective contraceptive measure throughout study . Provide write informed consent . Symptomatic brain metastasis stable , require steroid , potentially lifethreatening require radiation within last 28 day . History allergic reaction attribute similar compound study drug . Significant cardiac disease unless well control , poorly control hypertension . Active uncontrolled infection serious illness medical condition could interfere participation . History psychiatric condition might impair patient 's ability provide inform consent participate . Concurrent anticancer therapy . Use CYP3A4 inducers/inhibitors 14 day prior first dose . Pregnant breastfeeding female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Small cell lung cancer</keyword>
	<keyword>Uterine cancer</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Renal cancer</keyword>
	<keyword>Head neck cancer</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Gastrointestinal stromal tumor</keyword>
</DOC>